BioCentury | Jul 27, 2017
Clinical News

CHMP recommends against Vanda's Fanaptum for schizophrenia

...of an MAA for Fanaptum iloperidone from Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) to treat schizophrenia. The serotonin (5-HT2) receptor...
...U.S. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), Washington, D.C. Product: Fanaptum iloperidone (Fanapt) Business: Neurology Alicia Parker Fanapt Fanaptum iloperidone Vanda Pharmaceuticals Inc. Serotonin (5-HT2) receptor dopamine...
BioCentury | Jul 21, 2017
Company News

Vanda, Nektar get thumbs down from CHMP MAA for the candidate. FDA has approved the drug as Fanapt. It is a serotonin (5-HT2) receptor...
...Vanda fell $0.10 to $16.40 on Friday. Nektar gained $0.07 to $22.24. Alicia Parker Fanaptum Onzeald Nektar Therapeutics Vanda Pharmaceuticals Inc. Serotonin (5-HT2) receptor Topoisomerase...
BioCentury | Oct 31, 2016
Company News

Vanda, Taro Pharmaceutical deal

...Fanapt prior to the date, the license will be effective May 2, 2028. Fanapt, a serotonin (5-HT2) receptor...
BioCentury | Jun 6, 2016
Clinical News

Fanapt iloperidone regulatory update

...the Phase III REPRIEVE trial (see BioCentury, July 27, 2015). In 2009, FDA approved the serotonin (5-HT2) receptor...
BioCentury | Jan 11, 2016
Clinical News

Fanapt iloperidone regulatory update

...Fanaptum iloperidone to treat schizophrenia in adults. In 2013, Vanda withdrew an MAA for the serotonin (5-HT2) receptor...
BioCentury | Aug 24, 2015
Company News

Allergan, Merck sales and marketing update

...plc ., which changed its name to Allergan, has exclusive, U.S. marketing rights to the serotonin (5-HT2) receptor...
BioCentury | Jul 27, 2015
Clinical News

Fanapt iloperidone: Interim Phase III data

...NASDAQ:VNDA), Washington, D.C. Product: Fanapt iloperidone Business: Neurology Molecular target: Serotonin (5-HT2) receptor ; Dopamine receptor Description: Serotonin (5-HT2) receptor...
BioCentury | Mar 30, 2015
Clinical News

Saphris asenapine regulatory update

...schizophrenia in adults. Actavis plc (NYSE:ACT, Dublin, Ireland) has exclusive U.S. marketing rights to the serotonin (5-HT2) receptor...
BioCentury | Jan 5, 2015
Company News

Novartis, Vanda deal

...Novartis. Novartis had U.S. and Canadian rights to the drug under a 2009 deal. The serotonin (5-HT2) receptor...
BioCentury | Dec 24, 2014
Company News

Vanda climbs on Fanapt settlement

...seeking $539 million from Novartis. Vanda will regain territorial rights on Dec. 31 to the serotonin (5-HT2) receptor...
Items per page:
1 - 10 of 128